New asthma drug shows promise in real-world greek study

NCT ID NCT05440656

First seen Apr 29, 2026 · Last updated May 12, 2026 · Updated 3 times

Summary

This study followed 152 adults in Greece with severe eosinophilic asthma who were starting benralizumab, a medication that helps control the condition. Over 48 weeks, researchers measured not only standard asthma control but also quality of life, sleep, mood, and physical activity using wearable trackers. The goal was to see how the drug works in routine care and how it affects patients' daily well-being.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE EOSINOPHILIC ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Alexandroupoli, 68100, Greece

  • Research Site

    Athens, 11521, Greece

  • Research Site

    Athens, 11527, Greece

  • Research Site

    Athens, 12462, Greece

  • Research Site

    Athens, 15125, Greece

  • Research Site

    Athens, 17562, Greece

  • Research Site

    Corfu, 49100, Greece

  • Research Site

    Heraklion, 71500, Greece

  • Research Site

    Ioannina, 45500, Greece

  • Research Site

    Rio, 26504, Greece

  • Research Site

    Thessaloniki, 55535, Greece

  • Research Site

    Thessaloniki, 56429, Greece

  • Research Site

    Thessaloniki, 57010, Greece

Conditions

Explore the condition pages connected to this study.